Screener
Agios Pharmaceuticals AGIO Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value |
|---|---|---|---|---|
| Corporate debt securities | 332,977 | 100 | (264) | 332,813 |
| Total current | 518,056 | 206 | (333) | 517,929 |
| Non-current: | ||||
| U.S. Treasuries | 155,754 | 15 | (951) | 154,818 |
| Government securities | 57,467 | 17 | (220) | 57,264 |
| Corporate debt securities | 135,701 | 2 | (531) | 135,172 |
| Total non-current | 348,922 | 34 | (1,702) | 347,254 |
| Total marketable securities | $866,978 | $240 | $(2,035) | $865,183 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's unrealized gains on investments?
- Agios Pharmaceuticals (AGIO) reported unrealized gains on investments of $206K in Q2 2026.
- How has Agios Pharmaceuticals's unrealized gains on investments changed year-over-year?
- Agios Pharmaceuticals's unrealized gains on investments decreased by 85.2% year-over-year, from $1.39M to $206K.
- What is the long-term trend for Agios Pharmaceuticals's unrealized gains on investments?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's unrealized gains on investments has grown at a 30.8% compound annual growth rate (CAGR), from $321K to $1.23M.
Ask your AI about Agios Pharmaceuticals's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude